On Friday, Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares surged 4.01% to $28.56, as on April 6, a biopharmaceutical company, declared that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, counting breast cancer. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome.
EMERGE was a randomized, multi-center, controlled study. 124 patients with advanced, heavily pre-treated (2-7 lines of preceding chemotherapy counting a taxane, an anthracycline, capecitabine, and, if HER2-positive, trastuzumab and lapatinib) breast cancer were enrolled and randomized (2:1) to receive glembatumumab vedotin or “Investigator’s Choice” (IC) single agent, approved chemotherapy. The primary endpoint of the study was overall response rate. Secondary endpoints comprised of duration of response, progression-free survival, overall survival, safety, and pharmacokinetic and pharmacodynamic analyses. gpNMB expression levels were evaluated via central immunohistochemistry on archived tumor tissue.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
California Resources Corporation (NYSE:CRC)’s shares gained 3.96% to $8.41, during the last trading session on Friday, as an oil and natural gas exploration and production company, will host its first quarter financial results conference call on Thursday, April 30th at 5:00 pm Eastern Daylight Time. The Company’s earnings will be released following the market close on the same date.
California Resources Corporation operates as an oil and natural gas exploration and production company in the State of California. It produces oil, natural gas, and natural gas liquids. The company holds interests in about 2.4 million net acres. It also gathers, processes, and markets oil and gas products, in addition to produces and sells power. The company is headquartered in Los Angeles, California.
At the end of Friday’s trade, Compania de Minas Buenaventura SAA (NYSE:BVN)’s shares gained 3.84% to $10.82, after Peru’s largest publicly traded, precious metals mining company declared preliminary 1Q15 production results and 2015 operating guidance.
Compañía de Minas Buenaventura S.A.A., a precious metals company, is engaged in the exploration, mining, and processing of gold and silver. It also explores for other metals, counting lead, zinc, and copper.
Finally, CIT Group Inc. (NYSE:CIT), ended its Friday’s trading session with 3.78% gain, and closed at $47.20, as the holding company for CIT bank will issue its financial results for the quarter, before the market opens on Tuesday, April 28, 2015 and will hold a conference call and audio webcast to talk about the results at 8:00 AM EDT.
CIT Group Inc. operates as the holding company for CIT bank that provides commercial financing and leasing products; and a suite of savings options in the United States. Its Transportation & International Finance segment offers leasing and financing solutions to operators and suppliers in the aviation and railcar industries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
